{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:36:35Z","timestamp":1790231795011,"version":"4.1.0"},"reference-count":81,"publisher":"BMJ","license":[{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Guidelines on the treatment of tuberculosis (TB) have essentially remained the same for the past 35 years, but are now starting to change. Ongoing clinical trials will hopefully transform the landscape for treatment of drug sensitive TB, drug resistant TB, and latent TB infection. Multiple trials are evaluating novel agents, repurposed agents, adjunctive host directed therapies, and novel treatment strategies that will increase the probability of success of future clinical trials. Guidelines for HIV-TB co-infection treatment continue to be updated and drug resistance testing has been revolutionized in recent years with the shift from phenotypic to genotypic testing and the concomitant increased speed of results. These coming changes are long overdue and are sorely needed to address the vast disparities in global TB incidence rates. TB is currently the leading cause of death globally from a single infectious agent, but the work of many researchers and the contributions of many patients in clinical trials will reduce the substantial global morbidity and mortality of the disease.<\/jats:p>","DOI":"10.1136\/bmj.m216","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T11:25:17Z","timestamp":1583148317000},"page":"m216","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":58,"title":["Current and future treatments for tuberculosis"],"prefix":"10.1136","author":[{"given":"Anthony","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingda Linda","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifton E","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray Y","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"key":"key20200309000105_ref1","unstructured":"World Health Organization. Global TB Report 2019. 2019. https:\/\/www.who.int\/tb\/publications\/global_report\/en\/"},{"key":"key20200309000105_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-4079(19)33007-9"},{"key":"key20200309000105_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/0007-0971(81)90022-X"},{"key":"key20200309000105_ref4","first-page":"S231","article-title":"Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications","volume":"3","author":"Fox","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"key20200309000105_ref5","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00309102"},{"key":"key20200309000105_ref6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200411-1603OE"},{"key":"key20200309000105_ref7","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201509-632PS"},{"key":"key20200309000105_ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407426"},{"key":"key20200309000105_ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314210"},{"key":"key20200309000105_ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315817"},{"key":"key20200309000105_ref11","first-page":"6","article-title":"The curious characteristics of pyrazinamide: a review","volume":"7","author":"Zhang","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"key":"key20200309000105_ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00764-2"},{"key":"key20200309000105_ref13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201806-1140ED"},{"key":"key20200309000105_ref14","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201410-1843OC"},{"key":"key20200309000105_ref15","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201712-2524OC"},{"key":"key20200309000105_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30274-2"},{"key":"key20200309000105_ref17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200904-0536OC"},{"key":"key20200309000105_ref18","doi-asserted-by":"publisher","DOI":"10.12688\/gatesopenres.12750.1"},{"key":"key20200309000105_ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2016.02.863"},{"key":"key20200309000105_ref20","unstructured":"World Health Organization. WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis. 2018. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/260494\/9789241550079-eng.pdf;jsessionid=9E2BD49130618683CDA3C987CABB97D1?sequence=1"},{"key":"key20200309000105_ref21","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0077OC"},{"key":"key20200309000105_ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811867"},{"key":"key20200309000105_ref23","unstructured":"World Health Organization. Consolidated guidelines on drug-resistant tuberculosis treatment. 2019. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/311389\/9789241550529-eng.pdf"},{"key":"key20200309000105_ref24","unstructured":"World Health Organization. Rapid Communication: Key changes to the treatment of drug-resistant tuberculosis. 2019. https:\/\/www.who.int\/tb\/publications\/2019\/WHO_RapidCommunicationMDR_TB2019.pdf?ua=1"},{"key":"key20200309000105_ref25","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90815-4"},{"key":"key20200309000105_ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6832"},{"key":"key20200309000105_ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30363-7"},{"key":"key20200309000105_ref28","unstructured":"US Food and Drug Administration. FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs"},{"key":"key20200309000105_ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201964"},{"key":"key20200309000105_ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30455-7"},{"key":"key20200309000105_ref31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201025"},{"key":"key20200309000105_ref32","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12777"},{"key":"key20200309000105_ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2018.08.001"},{"key":"key20200309000105_ref34","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.870884"},{"key":"key20200309000105_ref35","first-page":"1","article-title":"Tuberculosis. Scientific blueprint for tuberculosis drug development","volume":"81","author":"O\u2019Brien","year":"2001","journal-title":"Tuberculosis (Edinb)"},{"key":"key20200309000105_ref36","unstructured":"US Food and Drug Administration. Guidance for industry: pulmonary tuberculosis: developing drugs for treatment. 2013. https:\/\/www.fda.gov\/media\/87194\/download"},{"key":"key20200309000105_ref37","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix247"},{"key":"key20200309000105_ref38","doi-asserted-by":"publisher","DOI":"10.1002\/iub.1866"},{"key":"key20200309000105_ref39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002773"},{"key":"key20200309000105_ref40","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3937"},{"key":"key20200309000105_ref41","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001098"},{"key":"key20200309000105_ref42","doi-asserted-by":"publisher","DOI":"10.7326\/M17-1150"},{"key":"key20200309000105_ref43","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6725a5"},{"key":"key20200309000105_ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714283"},{"key":"key20200309000105_ref45","doi-asserted-by":"publisher","DOI":"10.5588\/pha.14.0089"},{"key":"key20200309000105_ref46","unstructured":"Frick M. An activist\u2019s guide to rifapentine for the treatment of TB infection. 2019. http:\/\/www.treatmentactiongroup.org\/sites\/default\/files\/rifapentine_guide_2019_web_final2.pdf"},{"key":"key20200309000105_ref47","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-019-0380-2"},{"key":"key20200309000105_ref48","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01316-1"},{"key":"key20200309000105_ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2017.11.009"},{"key":"key20200309000105_ref50","unstructured":"Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2019. https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf"},{"key":"key20200309000105_ref51","unstructured":"Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the CDC, the NIH, and the IDSA. 2019. https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adult_oi.pdf"},{"key":"key20200309000105_ref52","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(17)30372-8"},{"key":"key20200309000105_ref53","doi-asserted-by":"crossref","unstructured":"TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 2015;373:808-22.","DOI":"10.1056\/NEJMoa1507198"},{"key":"key20200309000105_ref54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506816"},{"key":"key20200309000105_ref55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014181"},{"key":"key20200309000105_ref56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013911"},{"key":"key20200309000105_ref57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013607"},{"key":"key20200309000105_ref58","unstructured":"US Department of Health and Human Services. Clinical Guidelines. 2020. https:\/\/aidsinfo.nih.gov\/guidelines"},{"key":"key20200309000105_ref59","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70733-9"},{"key":"key20200309000105_ref60","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70692-3"},{"key":"key20200309000105_ref61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806808"},{"key":"key20200309000105_ref62","unstructured":"Dooley KE, Churchyard GJ, Savic RM, et al. Safety and PK of weekly rifapentine\/isoniazid (3HP) in adults with HIV on dolutegravir. In: Conference on Retroviruses and Opportunistic Infections. Seattle, WA: 2019. http:\/\/www.croiconference.org\/sessions\/safety-pk-weekly-rifapentineisoniazid-3hp-adults-hiv-dolutegravir"},{"key":"key20200309000105_ref63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907847"},{"key":"key20200309000105_ref64","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30691-6"},{"key":"key20200309000105_ref65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614915"},{"key":"key20200309000105_ref66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800474"},{"key":"key20200309000105_ref67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1811861"},{"key":"key20200309000105_ref68","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-019-0214-5"},{"key":"key20200309000105_ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2017.09.005"},{"key":"key20200309000105_ref70","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00071-7"},{"key":"key20200309000105_ref71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002794"},{"key":"key20200309000105_ref72","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw376"},{"key":"key20200309000105_ref73","unstructured":"World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care. 2017. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255052\/9789241550000-eng.pdf"},{"key":"key20200309000105_ref74","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.18.0622"},{"key":"key20200309000105_ref75","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30263-2"},{"key":"key20200309000105_ref76","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment. Geneva: 2020. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/331170\/9789240001503-eng.pdf?sequence=1&isAllowed=y."},{"key":"key20200309000105_ref77","first-page":"1","article-title":"Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Reports","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key20200309000105_ref78","unstructured":"Dooley KE, Rosenkranz SL, Conradie F, et al. QT effects of bedaquiline, delamanid or both in MDR-TB patients: the DELIBERATE trial. Abstract 84. In: Conf Retroviruses Opportun Infect. Seattle, WA. 2019. https:\/\/www.croiconference.org\/sessions\/qt-effects-bedaquiline-delamanid-or-both-mdr-tb-patients-deliberate-trial"},{"key":"key20200309000105_ref79","unstructured":"World Health Organization. A patient-centred approach to TB care. 2018. https:\/\/www.who.int\/iris\/handle\/10665\/272467"},{"key":"key20200309000105_ref80","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix373"},{"key":"key20200309000105_ref81","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.17.0608"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.m216","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.m216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T00:03:23Z","timestamp":1601078603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.m216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,2]]},"references-count":81,"alternative-id":["10.1136\/bmj.m216"],"URL":"https:\/\/doi.org\/10.1136\/bmj.m216","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,2]]}}}